
    
      To assess the safety of an investigational intravenous iron (ferric carboxymaltose [FCM]) or
      an equal dose of iron dextran and explore the mechanism of hypophosphatemia following
      administration of FCM or that of an equal dose of iron dextran when treating women with iron
      deficiency anemia due to heavy uterine bleeding (HUB).
    
  